Rio de Janeiro, Brazil

Roberto Takashi Sudo

This inventor holds 2 USPTO granted patents. Top assignees: Cristalia Productos Quimicos Farmaceuticos Ltda., University System of Maryland. Active years: 2006-2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Roberto Takashi Sudo. Retrieved from https://idiyas.com/inventor/roberto-takashi-sudo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 4.9

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2006-2010

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations and Contributions of Roberto Takashi Sudo

Introduction

Roberto Takashi Sudo is a notable inventor based in Rio de Janeiro, Brazil. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative methods for anesthesia and cardiac treatment. With a total of 2 patents, his work reflects a commitment to advancing medical science.

Latest Patents

One of Sudo's latest patents focuses on the use of a non-racemic mixture of bupivacaine enantiomers to improve the anesthesia profile. This invention describes a new method for the separation of bupivacaine enantiomers through a continuous separation process that avoids heating. By utilizing selective precipitation of diastereomeric salts with tartaric acid, this heatless process prevents the degradation of reagents, allowing for a continuous procedure. The enantiomeric manipulation of bupivacaine enantiomers leads to pharmaceutical compositions with varying enantiomeric excess of levobupivacaine, which helps quantify the role of dextrobupivacaine in anesthetic and cardiotoxic effects. These manipulated compositions demonstrate enhanced anesthetic properties comparable to racemic bupivacaine while maintaining a cardiotoxic profile similar to pure levobupivacaine.

Another significant patent involves a compound with digitalis-like properties, which produces positive inotropic effects. This invention discloses a novel method to synthesize 3,4-methylenedioxybenzoyl-2-thienylhydrazone (LASSBio-294). LASSBio-294 is beneficial for treating congestive heart failure and muscle fatigue, lacking the toxic effects associated with digitalis glycosides.

Career Highlights

Throughout his career, Sudo has worked with reputable organizations, including the University System of Maryland and Cristalia Produtos Quimicos Farmaceuticos Ltda. His experience in these institutions has contributed to his expertise in pharmaceutical innovations.

Collaborations

Sudo has collaborated with notable professionals in his field, including Edson X Albuquerque and Eliezer J De Barreiro. These partnerships have further enriched his research and development efforts.

Conclusion

Roberto Takashi Sudo's contributions to the field of pharmaceuticals through his innovative patents highlight his dedication to improving medical treatments. His work continues to influence the development of safer and

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…